Prognosis and Management of Intermediate-Risk Prostate Cancer

Current Risk Assessment

• The National Comprehensive Cancer Network recommends that a patient with a Genomic Prostate Score of 28 has only 1% risk of prostate cancer death within 10 years and 5% risk of metastasis, indicating favorable intermediate-risk prostate cancer 1
• A Gleason 7 (3+4) diagnosis in only 10% of one core represents minimal disease burden, with the National Comprehensive Cancer Network providing guidance on risk assessment 1
• The Genomic Prostate Score of 28 places the patient in a favorable intermediate-risk category, with a 36% risk of adverse pathology if treated, according to the National Comprehensive Cancer Network 1

Recommended Next Steps

• The National Comprehensive Cancer Network recommends obtaining a repeat 3T multiparametric MRI to assess current disease status and guide decision-making for patients with intermediate-risk prostate cancer 1, 2
• The American Family Physician suggests that MRI findings will determine whether additional targeted biopsy is warranted, highlighting the importance of imaging in treatment decisions 2, 5

Treatment Decision Algorithm

• The National Comprehensive Cancer Network recommends that for a patient with life expectancy >10 years and favorable intermediate-risk disease, definitive treatment should be strongly considered rather than continued surveillance 1, 2
• Radical prostatectomy offers 96% 5-year biochemical progression-free survival for this risk category, according to Praxis Medical Insights 2
• External beam radiation therapy + short-course ADT significantly improves outcomes for intermediate-risk disease, with a minimum radiation dose of 66 Gy and 4-6 months of androgen deprivation therapy, as recommended by Praxis Medical Insights 2

Urgency Assessment

• The Annals of Oncology suggests that this situation is semi-urgent but not emergent, with treatment decisions that should be made within 2-3 months, not delayed beyond 6 months 3, 2
• The National Comprehensive Cancer Network recommends that rising PSA trend, Gleason 7 (3+4) disease, and metastatic potential increase with time, though 10-year metastasis risk remains only 5% 1, 3

Monitoring If Treatment Deferred

• The National Comprehensive Cancer Network recommends implementing an intensive monitoring protocol if treatment is deferred, including PSA every 3 months, repeat MRI in 6 months, and digital rectal examination every 3-6 months 1, 4, 3, 2